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The thermal amplitude test is performed to determine the 
reactivity of a cold autoantibody at varying temperatures: 4°C, 
22°C, 30°C, and 37°C. Cold autoantibodies that are reactive at 
temperatures greater than 30°C have the potential to be clinically 
significant regardless of the antibody titer. Cold autoantibodies 
that are reactive at temperatures less than 30°C are not 
considered to be clinically significant. Immunohematology 
2013;29:49–50.
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Principle
Cold autoantibodies and agglutinins are naturally 
occurring in most people, and incidental cold agglutinins are 
seen in normal healthy blood donors at low titers (<1:64).1 
These benign cold autoantibodies are reactive at 4°C and have 
little or no reactivity at temperatures greater than 30°C. Cold 
autoantibodies may become clinically significant, resulting 
in red blood cell (RBC) hemolysis, if their titer increases or if 
they become reactive at temperatures greater than 30°C.2 Cold 
agglutinin disease (CAD) is hemolytic anemia secondary to 
cold autoantibodies and is responsible for approximately 13 
to 15 percent of total cases of autoimmune hemolytic anemia 
(AIHA).3 It is characterized by immunoglobulin (Ig) M (and, 
rarely, IgG) autoantibodies, which cause agglutination of 
RBCs in vitro at room temperature and can cause hemolysis 
in vivo if the antibody is reactive at temperatures greater than 
30°C and present at sufficient titers.2,4 These autoantibodies 
are usually directed against I, i, and related RBC antigens.1 The 
autoantibodies reactive at temperatures greater than 30°C may 
cause RBC hemolysis through activation of the complement 
pathway, leading to formation of membrane attack complex on 
the RBC membrane and intravascular hemolysis, or they may 
cause extravascular hemolysis via phagocytosis of C3b-coated 
RBCs by macrophages.2 Combined cold and warm AIHA 
(mixed AIHA) occurs when a patient has both warm AIHA 
and CAD.
Indications
Benign cold autoantibodies may be detected in the serum 
of many normal individuals. Pathologic cold autoantibodies 
capable of causing intravascular or extravascular hemolysis and 
CAD are characterized as having reactivity at cold temperatures 
(4°C–18°C) and warm temperatures (30°C–37°C) and are of 
high titer (>1:512 at 4°C).5–7 Both benign and pathologic cold 
autoantibodies may be seen in patients with warm AIHA. 
Patients with clinical and laboratory evidence of immune-
mediated hemolytic anemia and a detectable cold autoantibody 
need additional evaluation to determine the significance of 
this cold autoantibody. The thermal amplitude of the cold 
autoantibody, defined as the highest temperature at which the 
autoantibody binds the RBC antigen, most accurately predicts 
severity of the disease.2,6,7
Reagents/Supplies
Reagents Supplies
• Two examples of a 3%–5% 
saline suspension of Group O 
(I+) washed RBCs
• RBCs chosen should lack any 
RBC antigens for which the 
patient has known antibodies
• 0.9% saline
• Water baths at 37°C, 30°C,  
and 22°C






RBC = red blood cell.
Procedural Steps
• Warm RBCs and patient sample to 37°C separately
• Mix patient sample and RBCs
• Incubate mixture at 37°C for 1 hour
• Centrifuge the mixture and return to 37°C for 5 minutes
• Read for agglutination
• Incubate mixture at 30°C for 1 hour
• Centrifuge the mixture and return to 30°C for 5 minutes
• Read for agglutination
• Incubate mixture at 22°C for 1 hour
• Centrifuge mixture and return to 22°C for 5 minutes
• Read for agglutination
• Interpret results
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Procedure
Obtain an appropriate sample for testing (Tables 1, 2). The 
patient’s sample should be collected and maintained at 37°C 
until the serum and the RBCs can be separated. This is done to 
avoid in vitro autoadsorption. Alternatively, an EDTA plasma 
sample can be used if it is warmed to 37°C with repeated 
mixing and then separated for testing.5 Before performing 
the thermal amplitude test, the patient’s sample should be 
evaluated for antibodies to clinically significant antigens, and 
appropriate antibody identification or exclusion should be 
performed. Prepare two different examples of washed 3 to 5 
percent saline suspensions of group O adult (I+) RBCs. If the 
patient has an identified antibody to an RBC antigen, the cells 
selected should lack this antigen to prevent falsely positive 
results. Label two tubes appropriately. Warm the tubes, 
serum, and RBCs separately until they reach 37°C (about 
5–10 minutes). For each RBC suspension to be tested, place 
one drop of RBCs and three drops of serum into each of the 
warmed test tubes. Mix well and incubate at 37°C for 1 hour. 
Centrifuge according to the appropriate time and speed based 
on current calibrations for serologic agglutination testing 
for the centrifuge. Return the tubes to the 37°C water bath 
for 5 minutes before reading. Examine and grade the tubes 
for agglutination and record results. Transfer the tubes to a 
30°C water bath and incubate for 1 hour. Remove the tubes 
and centrifuge. Place the centrifuged tubes back into the 30°C 
water bath for 5 minutes before reading the results. Examine 
and grade the tubes for agglutination and record results. Last, 
transfer the tubes to a 22°C water bath and allow them to 
incubate for 1 hour. Centrifuge the tubes and return them to 
22°C for 5 minutes. After the tubes have incubated, examine 
and grade them for agglutination. Record the results.
An alternative to using centrifugation is to use the 
settling method in which the 37°C and 30°C incubations are 
extended to 2 hours each and the tubes are then examined for 
agglutination without centrifugation. The tubes undergoing 
room tempera-ture incubation can be centrifuged after 30 
minutes or 1 hour at 22°C.8
Interpret the results. If agglutination is present at 22°C but 
not at 30°C, then the antibody has limited thermal amplitude. 
If agglutination is observed at 30°C but not 37°C, then the 
antibody may have the potential to be clinically significant. If 
agglutination is observed at 37°C, then the antibody should be 
considered clinically significant.9
In addition, the literature suggests that if no reactivity 
is observed at 30°C and the patient has hemolytic anemia, 
then an additional test at 30°C using 30 percent albumin 
may be helpful to further distinguish a clinically significant 
antibody capable of causing RBC destruction from a clinically 
insignificant cold autoantibody.8,10
Limitations
Proper sample collection is critical to obtain valid results 
for this test. Improper sample collection can lead to in vitro 
autoadsorption of the cold autoantibody and falsely negative 
results. Choosing antigen-negative RBCs for patients with 
known antibodies is critical to preventing falsely positive 
results.
References
 1. Duffy TP. Autoimmune hemolytic anemia and paroxysmal 
nocturnal hemoglobinuria. In: Simon TL, Snyder EL, Solheim 
BG, Stowell CP, Strauss RG, Petrides M, eds. Rossi’s principles 
of transfusion medicine. 4th ed. Oxford, UK: Wiley-Blackwell, 
2004:328–31.
 2. Silberstein LE, Cunningham MJ. Autoimmune hemolytic 
anemias. In: Hillyer CD, ed. Blood banking and transfusion 
medicine, basic principles and practice. 2nd ed. New York, NY: 
Churchill Livingstone, 2007:563–5.
 3. Lechner K, Jäger U. How I treat autoimmune hemolytic 
anemias in adults. Blood 2010;116:1831–8.
 4. Elghetany MT, Banki K. Erythrocytic disorders. In: 
McPherson RA, Pincus MR, eds. Henry’s clinical diagnosis and 
management by laboratory methods. 21st ed. Philadelphia, PA: 
WB Saunders, 2007:504–42.
 5. Roback JD, Grossman BJ, Harris T, Hillyer CD, eds. 
AABB technical manual. 17th ed. Arlington, VA: American 
Association of Blood Banks, 2011:509.
 6. Gertz MA. Cold agglutinin disease. Haematologica 2005; 
91:439–41.
 7. Berentsen S, Beiske K, Tjønnfjord GE. Primary chronic cold 
agglutinin disease: an update on the pathogenesis, clinical 
features and therapy. Hematology 2007;12:361–70.
 8. Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. New 
York, NY: Churchill Livingstone, 2003:222.
 9. Judd WJ, Johnson ST, Storry JR. Judd’s methods in 
immunohematology. 3rd ed. Arlington, VA: American 
Association of Blood Banks, 2008:435–7.
 10. Garratty G, Petz LD, Hoops JK. The correlation of cold 
agglutinin titrations in saline and albumin with haemolytic 
anaemia. Br J Haematol 1977;35:587–95.
Courtney Hopkins, DO (corresponding author), Medical Director, 
and Tiffany K. Walters, MT(ASCP)SBBCM, Immunohematology 
Reference Lab Manager, South Carolina Blood Services, American 
Red Cross, 2751 Bull Street, Columbia, SC 29201.
S
E
R
O
L
O
G
IC
 M
E
T
H
O
D
 R
E
V
IE
W
